{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:20:35Z","timestamp":1791584435750,"version":"4.3.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100006282","name":"King Baudouin Foundation","doi-asserted-by":"publisher","award":["2016-J1820640-103933stu"],"award-info":[{"award-number":["2016-J1820640-103933stu"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The World Health Organization recommends 2 doses of human papillomavirus (HPV) vaccine for adults without human immunodeficiency virus (HIV) but 3 doses in persons with HIV. There are no immunogenicity data on the 2-dose schedule in women with HIV (WWH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective study comparing 2 doses (months 0 and 6) versus 3 (months 0, 2, and 6) doses of 9-valent vaccine (Gardasil 9, Merck Sharp &amp; Dohme) in WWH (15\u201340 years), on antiretrovirals with HIV RNA &amp;lt;400\u2005copies\/mL, enrolled during 2018\u20132021. After an open-label phase assessing safety (n = 45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was noninferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to the COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n = 22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n = 100) and per protocol on the whole cohort (n = 167).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants\u2019 median age was 35 years, median CD4 count was 649 cells\/\u00b5L, and 16 missed the month 7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined noninferiority criteria. At month 7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2\u20132.4 log10). There were no serious adverse events; participants with 3 doses experienced local reactions more frequently (82% vs 60% for 2 doses, P = .027) with more symptoms and longer duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In women with well-controlled HIV, 2 doses of 9-valent HPV vaccine is noninferior to 3 doses in terms of seroconversion and is associated with less reactogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT03391921; EUDRACT 2018-000228-33; CTIS-EMA 2024-520419-42-00.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf241","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T07:35:44Z","timestamp":1747035344000},"page":"673-681","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-9289","authenticated-orcid":false,"given":"Deborah","family":"Konopnicki","sequence":"first","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Gilles","sequence":"additional","affiliation":[{"name":"Gynecology Department, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Manigart","sequence":"additional","affiliation":[{"name":"Gynecology Department, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Barlow","sequence":"additional","affiliation":[{"name":"Gynecology Department, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Reschner","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coca","family":"Necsoi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-4158","authenticated-orcid":false,"given":"Davy","family":"Vanden Broeck","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pathology Algemeen Medisch Laboratorium, Sonic Healthcare Belgium and Belgian National Reference Laboratory for Human Papillomavirus , Antwerp ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-6849","authenticated-orcid":false,"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Universit\u00e9 Libre de Bruxelles , Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2026043013105751800_ciaf241-B1","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2214-109X(20)30459-9","article-title":"Estimates of the global burden of cervical cancer associated with HIV","volume":"9","author":"Stelzle","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2026043013105751800_ciaf241-B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.32260","article-title":"Cervical cancer risk in women living with HIV across four continents: a multicohort study","volume":"146","author":"Rohner","year":"2020","journal-title":"Int J Cancer"},{"key":"2026043013105751800_ciaf241-B3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/cid\/ciy1123","article-title":"Residual or recurrent precancerous lesions after treatment of cervical lesions in human immunodeficiency virus\u2013infected women: a systematic review and meta-analysis of treatment failure","volume":"69","author":"Debeaudrap","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026043013105751800_ciaf241-B4","first-page":"CD009069","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026043013105751800_ciaf241-B5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026043013105751800_ciaf241-B6","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2026043013105751800_ciaf241-B7","doi-asserted-by":"crossref","first-page":"101585","DOI":"10.1016\/j.eclinm.2022.101585","article-title":"Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: a systematic review and meta-analysis","volume":"52","author":"Staadegaard","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026043013105751800_ciaf241-B8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/cid\/cit319","article-title":"Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women","volume":"57","author":"Kahn","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026043013105751800_ciaf241-B9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/infdis\/jit657","article-title":"Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial","volume":"209","author":"Toft","year":"2014","journal-title":"J Infect Dis"},{"key":"2026043013105751800_ciaf241-B10","author":"European AIDS Clinical Society"},{"key":"2026043013105751800_ciaf241-B11"},{"key":"2026043013105751800_ciaf241-B12"},{"key":"2026043013105751800_ciaf241-B13","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4161\/hv.29205","article-title":"Development of a human papillomavirus competitive Luminex immunoassay for 9 HPV types","volume":"10","author":"Roberts","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013105751800_ciaf241-B14","doi-asserted-by":"crossref","first-page":"e20154387","DOI":"10.1542\/peds.2015-4387","article-title":"Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials","volume":"138","author":"Moreira","year":"2016","journal-title":"Pediatrics"},{"key":"2026043013105751800_ciaf241-B15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1515\/cclm.2011.835","article-title":"High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR","volume":"50","author":"Micalessi","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"2026043013105751800_ciaf241-B16","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"key":"2026043013105751800_ciaf241-B17","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the 9-valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)","volume":"73","author":"Boey","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026043013105751800_ciaf241-B18","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2021.02.022","article-title":"Sex difference in the immunogenicity of the quadrivalent human papilloma virus vaccine: systematic review and meta-analysis","volume":"39","author":"Aldakak","year":"2021","journal-title":"Vaccine"},{"key":"2026043013105751800_ciaf241-B19","first-page":"425","article-title":"High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus","volume":"30","author":"Konopnicki","year":"2016","journal-title":"AIDS"},{"key":"2026043013105751800_ciaf241-B20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/cid\/ciu238","article-title":"Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1\u2013infected women","volume":"59","author":"Kojic","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026043013105751800_ciaf241-B21","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1016\/j.vaccine.2016.08.016","article-title":"HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine","volume":"34","author":"Money","year":"2016","journal-title":"Vaccine"},{"key":"2026043013105751800_ciaf241-B22","doi-asserted-by":"crossref","first-page":"2425146","DOI":"10.1080\/21645515.2024.2425146","article-title":"Immunogenicity of the 9-valent human papillomavirus vaccine: post hoc analysis from five phase 3 studies","volume":"21","author":"Giuliano","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013105751800_ciaf241-B23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"2026043013105751800_ciaf241-B24","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2018.1564436","article-title":"HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe","volume":"15","author":"Karafillakis","year":"2019","journal-title":"Hum Vaccin Immunother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf241\/63160688\/ciaf241.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/673\/63160688\/ciaf241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/673\/63160688\/ciaf241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:11:04Z","timestamp":1777569064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/673\/8129247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf241","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,5,13]]}}}